Aravive (ARAV) Stock Forecast, Price & News

Aravive (NASDAQ:ARAV) Frequently Asked Questions

Is Aravive a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive or view top-rated stocks.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive, Inc. (NASDAQ:ARAV) posted its earnings results on Thursday, May, 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.08. Aravive had a negative trailing twelve-month return on equity of 88.49% and a negative net margin of 533.99%.
View Aravive's earnings history.

What price target have analysts set for ARAV?

1 Wall Street analysts have issued 12 month target prices for Aravive's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Aravive's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 391.8% from the stock's current price.
View analysts' price targets for Aravive or view top-rated stocks among Wall Street analysts.

Who are Aravive's key executives?

Aravive's management team includes the following people:

• Dr. Fredric N. Eshelman Pharm.D., Exec. Chairman (Age 73, Pay $95k)
• Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D., Pres, CEO & Director (Age 59, Pay $699.7k)
• Mr. Vinay Shah MBA, Chief Financial Officer (Age 59, Pay $496.5k)
• Dr. Jeffrey L. Cleland Ph.D., Co-Founder (Age 57)
• Dr. Joshua Silverman Ph.D., Co-Founder
• Dr. Leonard Scott Dove Ph.D., Chief Operating Officer (Age 49)
• Mr. Marek Ciszewski J.D., VP of Investor Relations
• Dr. Randy L. Anderson, Sr. VP of Data Sciences
• Kenneth L. Guernsey, Sec.

Who are some of Aravive's key competitors?

Some companies that are related to Aravive include ORIC Pharmaceuticals (ORIC), ObsEva (OBSV), Cue Biopharma (CUE), Vascular Biogenics (VBLT), Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Spectrum Pharmaceuticals (SPPI), scPharmaceuticals (SCPH), ProPhase Labs (PRPH), IO Biotech (IOBT), Sol-Gel Technologies (SLGL), Applied Molecular Transport (AMTI), Pieris Pharmaceuticals (PIRS) and RVL Pharmaceuticals (RVLP).
View all of ARAV's competitors.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.17%), Renaissance Technologies LLC (1.32%), UBS Group AG (0.19%), Bradley & Co. Private Wealth Management LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Aravive stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah.
View institutional ownership trends for Aravive.

Which major investors are selling Aravive stock?

ARAV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and UBS Group AG.
View insider buying and selling activity for Aravive or view top insider-selling stocks.

Which major investors are buying Aravive stock?

ARAV stock was purchased by a variety of institutional investors in the last quarter, including Bradley & Co. Private Wealth Management LLC. Company insiders that have bought Aravive stock in the last two years include Gail Frances Mcintyre, and Vinay Shah.
View insider buying and selling activity for Aravive or or view top insider-buying stocks.

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $1.22.

How much money does Aravive make?

Aravive has a market capitalization of $35.17 million and generates $7.44 million in revenue each year. The company earns $-39.15 million in net income (profit) each year or ($2.12) on an earnings per share basis.

How many employees does Aravive have?

Aravive employs 17 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at (936) 355-1910 or via email at [email protected].